• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

The Rate of Undetected MASLD in the US is a Sobering Statistic, says Expert Hepatologist Naim Alkhouri, MD

Commentary
Video

Expert Interview

Alkhouri, a veteran investigator in the field of hepatic disease, including MASLD and MASH, stresses the need for early detection of MASLD when simple intervention can be effective.


On an average day an estimated 1 in 3 adults seated in a US primary care clinic waiting room may have metabolic dysfunction-associated liver disease, or MASLD, Naim Alkhouri, MD, said in a recent conversation with Patient Care.® If there are individuals in that group with type 2 diabetes, they represent a population in which 55% to 60% likely has MASLD. For the US population with severe obesity, the estimated percentage with MASLD is as high as 85% to 90%. Alkhouri, who is chief medical officer, chief of transplant hepatology, and director of the fatty liver program at Arizona Liver Health, in Phoenix, also emphasized that when detected early, before it can progress to metabolic dysfunction-associated steatohepatitis and advanced fibrosis, MASLD is a manageable disease. He explains more in the video above. (Follow Dr Alkhouri on X @AlkhouriNaim)

For additional details on the study mentioned during this interview, see: Harrison SA, Gawrieh S, Roberts K, et al. Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort. J Hepatol. 2021 Aug;75(2):284-291.


Other videos in this series with Dr Alkhouri:


Related Content
© 2024 MJH Life Sciences

All rights reserved.